Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.67 |
| ▸ | STAT3 | P40763 | 4/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.60 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | IL1B | P01584 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21259428 | 0.99 | CRBN (0.66) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL22892868 | 0.99 | CRBN (0.66) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL30670795 | 0.99 | CRBN (0.66) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL26918177 | 0.99 | CRBN (0.66) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL26917360 | 0.99 | CRBN (0.66) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL29880821 | 0.95 | CRBN (0.71) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL17536582 | 0.92 | CRBN (0.67) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL21996721 | 0.92 | CRBN (0.64) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL23974724 | 0.91 | CRBN (0.66) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL19475684 | 0.91 | CRBN (0.66) | CRBNDDB1STAT3CA2DYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376094-A2 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-11-14 | — | — | US | disclosed |
| WO-2024145315-A1 | TARGETED PROTEIN DEGRADERS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) | NORTHWESTERN UNIVERSITY (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240182464-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoirens Serviece (FR) | 2024-06-06 | — | — | US | disclosed |
| EP-4288434-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoires Servier (FR) | 2023-12-13 | — | — | EP | disclosed |
| US-20190247509-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247509-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BRD9, BRWD1, BRD1 | CRBN 186/4885DDB1 442/4885STAT3 2161/4885 |
| US-20240182464-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | CRBN, XIAP, BCL2L11 | CRBN 1/4885DDB1 148/4885STAT3 364/4885 |
| US-20240376094-A2 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | CRBN, XIAP, BCL2L11 | CRBN 1/4885DDB1 148/4885STAT3 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.